Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study. World J Gastroenterol 2019; 25(25): 3256-3267 [PMID: 31333316 DOI: 10.3748/wjg.v25.i25.3256]
Corresponding Author of This Article
Won Hyeok Choe, MD, PhD, Professor, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05030, South Korea. 20050101@kuh.ac.kr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 7, 2019; 25(25): 3256-3267 Published online Jul 7, 2019. doi: 10.3748/wjg.v25.i25.3256
Table 1 The baseline characteristics of the enrolled treatment-naïve chronic hepatitis B patients with normal or minimally raised alanine aminotransferase levels
Characteristics (n = 63)
Sex, male/female
37/26
Age, mean (± SD) yr
50.8 (± 8.9)
Body mass index, mean (± SD) kg/m2
23.4 (± 3.4)
AST, mean (± SD), IU/L (normal 4-40 IU/L)
43.5 (± 22.6)
ALT, mean (± SD), IU/L (normal 4-40 IU/L)
44.0 (± 20.8)
Platelet counts, mean (± SD), × 103/mm3
163.5 (± 39.4)
Prothrombin time, mean (± SD), INR
1.05 (± 0.08)
Total bilirubin, mean (± SD), mg/dL
0.75 (± 0.47)
Albumin, mean (± SD), g/dL
3.97 (± 0.24)
γ-glutamyl transferase, mean (± SD), U/L
47.5 (± 31.0)
HBeAg status, positive/negative
35/28
HBV-DNA, mean (± SD), log10 IU/mL
5.78 (± 1.64)
Grade of inflammatory activity (0/1/ 2/3)
9/26/15/13
Fibrosis stage (0/1/2/3 /4)
3/16/14/ 14/16
Table 2 Statistics of liver stiffness value measured by magnetic resonance elastography and two-dimensional shear wave elastography, fibrosis index based on four factors score, and aspartate transaminase-to-platelet ratio index score with the Spearman’s coefficients according to fibrosis stages
F0/F1 (n = 19)
F2 (n = 14)
F3 (n = 14)
F4 (n = 16)
r
P value
MRE
1.96 ± 0.43
2.46 ± 0.54
2.91 ± 0.45
3.91 ± 0.50
0.869
< 0.001
2D-SWE
6.09 ± 1.58
8.05 ± 2.23
8.16 ± 2.08
11.39 ± 3.01
0.649
< 0.001
FIB-4
1.75 ± 0.61
1.76 ± 0.60
2.48 ± 0.91
3.21 ± 1.45
0.517
< 0.001
APRI
0.58 ± 0.20
0.71 ± 0.46
0.95 ± 0.44
1.04 ± 0.58
0.431
< 0.001
Table 3 Factors associated with the values of liver stiffness measured by magnetic resonance elastography and two-dimensional shear wave elastography in univariate and multivariate linear regression analyses
Parameters
Factors associated with liver stiffness values by MRE
Factors associated with liver stiffness values by 2D-SWE
Univariate
P value
Multivariate
P value
Univariate
P value
Multivariate
P value
Sex, male/female
-0.054 (-0.508, 0.401)
0.815
0.685 (-0.840, 2.210)
0.372
Age, yr
0.019 (-0.006, 0.044)
0.132
0.067 (-0.017, 0.151)
0.117
BMI, kg/m2
-0.048 (-0.114, 0.018)
0.149
-0.251 (-0.469, -0.034)
0.024
-0.186 (-0.366, -0.007)
0.042
AST, U/L
0.007 (-0.003, 0.017)
0.157
0.032 (-0.001, 0.065)
0.054
ALT, U/L
0.002 (-0.009, 0.013)
0.674
0.000 (-0.037, 0.037)
0.995
PLT counts, × 103/mm3
-0.007 (-0.012, -0.001)
0.014
0.001 (-0.002, 0.005)
0.530
-0.027 (-0.045, -0.009)
0.004
-0.012 (-0.029, 0.004)
0.136
PT, INR
1.312 (-1.595, 4.220)
0.370
8.658 (-0.971, 18.288)
0.077
Total bilirubin, mg/dL
0.331 (-0.140, 0.802)
0.165
0.098 (-1.517, 1.713)
0.904
Albumin, g/dL
-0.540 (-1.510, 0.429)
0.270
-3.152 (-6.359, 0.055)
0.054
γ-GT, U/L
0.004 (-0.003, 0.011)
0.302
0.012 (-0.012, 0.036)
0.327
HBeAg status, +/-
0.166 (-0.282, 0.615)
0.461
1.052 (-0.445, 2.549)
0.165
HBV-DNA, log10 IU/mL
-0.051 (-0.189, 0.086)
0.456
-0.076 (-0.541, 0.389)
0.745
Inflammatory grade
0.363 (0.153, 0.573)
0.001
0.105 (-0.031, 0.241)
0.129
0.903 (0.163, 1.644)
0.018
0.220 (-0.411, 0.852)
0.487
Fibrosis stage
0.626 (0.520, 0.732)
< 0.001
0.609 (0.487, 0.731)
< 0.001
1.616 (1.116, 2.116)
< 0.001
1.276 (0.690, 1.863)
< 0.001
Table 4 Diagnostic performance of magnetic resonance elastography and two-dimensional shear wave elastography, fibrosis index based on four factors score, and aspartate transaminase-to-platelet ratio index for evaluation of significant fibrosis (≥ F2) and cirrhosis (F4)
AUC (95%CI)
P value
Cutoff
Sensitivity (%)
Specificity (%)
PPV (%)
NPV (%)
MRE
≥ F2
0.906 (0.806, 0.965)
< 0.001
> 2.47 (kPa)
81.8
94.7
97.3
69.2
F4
0.894 (0.791, 0.958)
< 0.001
> 3.46 (kPa)
88.9
97.8
94.1
95.6
2D-SWE
≥ F2
0.843 (0.730, 0.923)
< 0.001
> 6.73 (kPa)
84.1
68.4
86.0
65.0
F4
0.816 (0.698, 0.902)
< 0.001
> 9.50 (kPa)
77.8
80.0
60.9
90.0
FIB-4
≥ F2
0.697 (0.568, 0.806)
0.003
> 1.80
70.5
63.2
81.6
48.0
F4
0.786 (0.665, 0.880)
< 0.001
> 3.22
50.0
97.8
90.0
83.0
APRI
≥ F2
0.717 (0.590, 0.823)
0.001
> 0.49
84.1
52.6
80.4
58.8
F4
0.701 (0.572, 0.810)
0.006
> 0.96
50.0
84.4
562
80.9
Citation: Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study. World J Gastroenterol 2019; 25(25): 3256-3267